You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxybuprocaine
Accession NumberDB00892  (APRD00817)
TypeSmall Molecule
GroupsApproved
DescriptionOxybuprocaine is the name of a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions.
Structure
Thumb
Synonyms
4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid
4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester
4-Amino-3-N-butoxy-benzoesaeure-diaethylaminoaethylester
Benoxil
Benoxinate
BNX
Butoxyaminobenzoyldiethylaminoethanol
Oxibuprocaina
Oxybucaine
Oxybuprocainum
Oxyriprocaine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Minims Benoxinate Hydrochloride 0.4%drops.4 %ophthalmic; topicalChauvin Pharmaceuticals Limited1995-12-312003-07-08Canada
Unapproved/Other Products Not Available
International Brands
NameCompany
BenoxilSanten
CebesineChauvin Bausch & Lomb
ConjuncainNot Available
DorsacaineNot Available
LacriminSanten
NovesinNovartis
NovesineNovartis
PrescainaLlorens
Brand mixtures
NameLabellerIngredients
AltafluorAltaire Pharmaceuticals Inc.
Fluorescein Sodium & Benoxinate Hydrochloride Ophtalmic Solution, USPBausch & Lomb Inc
Fluorescein Sodium and Benoxinate HydrochlorideBausch & Lomb Incorporated
FluoroxWhite Ophthalmic Services & Supply Co Ltd
FluressAkorn, Inc.
Fluress Liq OphPilkington Barnes Hind
FluroxO Cu Soft, Inc.
Salts
Name/CASStructureProperties
Benoxinate hydrochloride
ThumbNot applicableDBSALT001482
Oxybuprocaine Hydrochloride
5987-82-6
Thumb
  • InChI Key: PRGUDWLMFLCODA-UHFFFAOYSA-N
  • Monoisotopic Mass: 344.186670511
  • Average Mass: 344.877
DBSALT000226
Categories
UNIIAXQ0JYM303
CAS number99-43-4
WeightAverage: 308.4158
Monoisotopic: 308.209992772
Chemical FormulaC17H28N2O3
InChI KeyInChIKey=CMHHMUWAYWTMGS-UHFFFAOYSA-N
InChI
InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
IUPAC Name
2-(diethylamino)ethyl 4-amino-3-butoxybenzoate
SMILES
CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentBenzoic acid esters
Alternative Parents
Substituents
  • Benzoate ester
  • Aminobenzoic acid or derivatives
  • Benzylether
  • Substituted aniline
  • Phenol ether
  • Benzoyl
  • Aniline
  • Alkyl aryl ether
  • Primary aromatic amine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed to temporarily numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed.
PharmacodynamicsOxybuprocaine is a local anaesthetic. It may be less irritating than tetracaine, and the onset and duration of action are similar to tetracaine.
Mechanism of actionOxybuprocaine binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxybuprocaine Action PathwayDrug actionSMP00400
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9769
Blood Brain Barrier+0.8876
Caco-2 permeable+0.6501
P-glycoprotein substrateSubstrate0.7085
P-glycoprotein inhibitor INon-inhibitor0.7586
P-glycoprotein inhibitor IINon-inhibitor0.9645
Renal organic cation transporterNon-inhibitor0.7172
CYP450 2C9 substrateNon-substrate0.8202
CYP450 2D6 substrateNon-substrate0.5953
CYP450 3A4 substrateSubstrate0.5624
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9093
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5247
Ames testNon AMES toxic0.7542
CarcinogenicityNon-carcinogens0.7336
BiodegradationNot ready biodegradable0.9764
Rat acute toxicity2.5543 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8356
hERG inhibition (predictor II)Non-inhibitor0.5406
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sola barnes hind
Packagers
Dosage forms
FormRouteStrength
Solution/ dropsophthalmic
Liquidophthalmic
Solutionophthalmic
Dropsophthalmic; topical.4 %
Prices
Unit descriptionCostUnit
Fluress eye drops2.29USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point216.5 °C at 2.00E+00 mm HgNot Available
water solubilityVery soluble (hydrochloride salt)Not Available
logP3.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.544 mg/mLALOGPS
logP3.3ALOGPS
logP3.05ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)19.76ChemAxon
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.79 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity90.64 m3·mol-1ChemAxon
Polarizability35.83 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.76 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Katsuyuki Inoo, Mitsuhiro Kawada, Kenjiro Mori, “Oxybuprocaine-Containing Analgesic/Antipruritic External Preparation.” U.S. Patent US20110124727, issued May 26, 2011.

US20110124727
General ReferencesNot Available
External Links
ATC CodesS01HA02D04AB03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (45.5 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Oxybuprocaine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxybuprocaine.
AmisulprideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Azaperone.
AzelastineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxybuprocaine.
BaclofenThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
BrimonidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxybuprocaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxybuprocaine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxybuprocaine.
ButacaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxybuprocaine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxybuprocaine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxybuprocaine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxybuprocaine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxybuprocaine.
CitalopramThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxybuprocaine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxybuprocaine.
CocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxybuprocaine.
CyclizineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxybuprocaine.
DapoxetineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxybuprocaine.
DextromoramideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxybuprocaine.
DezocineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxybuprocaine.
DifenoxinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
DoxylamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxybuprocaine.
DrotebanolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine.
EcgonineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Oxybuprocaine.
EntacaponeThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxybuprocaine.
EthanolOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Oxybuprocaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxybuprocaine.
EthosuximideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxybuprocaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxybuprocaine.
FexofenadineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxybuprocaine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxybuprocaine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxybuprocaine.
FluspirileneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Oxybuprocaine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxybuprocaine.
HalothaneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Oxybuprocaine.
HydrocodoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxybuprocaine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Oxybuprocaine.
KetamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxybuprocaine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxybuprocaine.
LithiumThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxybuprocaine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxybuprocaine.
Lu AA21004The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxybuprocaine.
MesoridazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Oxybuprocaine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxybuprocaine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxybuprocaine.
MetyrosineOxybuprocaine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxybuprocaine.
MilnacipranThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
MirtazapineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxybuprocaine.
MolindoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxybuprocaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
NabiloneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxybuprocaine.
NitrazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Opium.
OrphenadrineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxybuprocaine.
OsanetantThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxybuprocaine.
OxprenololThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxybuprocaine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paliperidone.
ParaldehydeOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Oxybuprocaine.
ParoxetineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxybuprocaine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxybuprocaine.
PerampanelThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxybuprocaine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxybuprocaine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pomalidomide.
PramipexoleOxybuprocaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxybuprocaine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Oxybuprocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Oxybuprocaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxybuprocaine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxybuprocaine.
PromethazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxybuprocaine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Oxybuprocaine.
PropoxycaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxybuprocaine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxybuprocaine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxybuprocaine.
RomifidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Romifidine.
RopiniroleOxybuprocaine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxybuprocaine.
RotigotineOxybuprocaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxybuprocaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxybuprocaine.
SertindoleThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxybuprocaine.
SuvorexantThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptOxybuprocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxybuprocaine.
TetrabenazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetrodotoxin.
ThalidomideOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxybuprocaine.
ThiamylalThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxybuprocaine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxybuprocaine.
ThiothixeneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxybuprocaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxybuprocaine.
TrazodoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxybuprocaine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxybuprocaine.
TrimipramineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxybuprocaine.
VigabatrinThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxybuprocaine.
ZolazepamThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxybuprocaine.
ZonisamideThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hung CH, Wang JJ, Chen YC, Chu CC, Chen YW: Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53. doi: 10.1016/j.neulet.2009.03.018. Epub 2009 Mar 11. [PubMed:19429093 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Draeger J, Schloot W, Wirt H: Interindividual differences of corneal sensitivity. Genetic aspects. Ophthalmic Paediatr Genet. 1985 Aug;6(1-2):291-5. [PubMed:4069587 ]
  2. Dubbels R, Schloot W: Studies on the metabolism of benoxinate by human pseudocholinesterase. Metab Pediatr Syst Ophthalmol. 1983;7(1):37-43. [PubMed:6621359 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23